Digital Health Remote Medicine AI-Powered

VISION 2027

Bridging Clinical Signals to Digital — Transforming pain tracking, structural questionnaires, and vital signs into actionable data parameters to power a next-generation digital healthcare ecosystem.

$500B Target Market Size
18 USPTO Provisional Filings
4 Core Patent Families

Our Vision

The Future We Envision

A preventive model of care where clinical insights are collected and synthesized in real time—enabling primary care physicians to remotely review data and intervene proactively, minimizing the need for unnecessary hospital visits. CyberMDCare is anchoring the future of virtual medicine.

Problem Statement

The Problem We Solve

The U.S. Medicare Advantage market is estimated at approximately $500 billion in federal expenditures annually. Yet as virtual care expands, consistently capturing clinical data and reliably verifying patient identity remain unresolved challenges.

The Data Gap

CMS has been phasing in the V28 HCC risk-adjustment model since 2024. This model demands robust clinical evidence, yet systematically accumulating such data in a fragmented telehealth environment remains a significant challenge.

The Trust Gap

In virtual care settings, verifying that the person receiving treatment is the actual insurance beneficiary is structurally difficult — a challenge directly tied to Medicare Advantage fraud risk.

CyberMDCare aims to address both gaps head-on through clinical data processing technology and biometric authentication.
※ Market size figures are reference estimates based on CMS FY2025 Medicare Advantage expenditure reports and do not guarantee any revenue or profit of the Company.

Core Technology

Core Technology Framework

01
Clinical Signal

P·Q·R Clinical Signal System

An advanced algorithmic framework designed to unify heterogeneous health vectors—specifically Pain coordinates, variable Questionnaires, and Respiratory/Vital Signs—into a single, standardized clinical signal stream for streamlined processing.

02
Evidence Engine

Clinical Evidence Engine

An optimized software engine—clinicalEvidenceEngine.ts—engineered to process multiple streams of clinical data concurrently, translating raw metrics into actionable clinical insights for healthcare providers.

03
Biometric

BioSignBox Biometric Signature

Our proprietary dual-biometric framework engineered to cross-verify intent by combining facial topography parameters, behavioral ink dynamics, and secure session logs—directly confronting the identity verification and beneficiary fraud challenges inherent in virtual care.

04
Cloud

Cloud Integration Architecture

Data routed from Bluetooth-enabled medical devices and mobile endpoints is securely encrypted and transmitted to dedicated cloud storage in strict compliance with HIPAA and federal privacy standards, allowing authorized physicians to retrieve and act on reference data securely at any time.

Integration Strategy

clinicalEvidenceEngine.ts & CMS V28 HCC Integration Strategy

Data Flow

Patient input & measurement → Encrypted channel → Cloud storage → Physician remote access → Clinical & preventive intervention

Core Approach

Our core technical approach is designing the P·Q·R signal system to systematically generate and accumulate the clinical evidence data required by the V28 HCC model.

1
V28 HCC Integration

The CMS V28 HCC model determines risk-adjusted payments for Medicare Advantage plans based on patient disease complexity and risk. We are developing a structure in which P·Q·R clinical data can systematically supply the evidence needed for HCC coding.

2
AWV & HEDIS Support

The platform aims to enable structured online collection and management of AWV (Annual Wellness Visit) and HEDIS (Healthcare Effectiveness Data) records. Both metrics directly influence Medicare Advantage Star Ratings, creating meaningful value for medical groups.

※ Currently in development and technical validation stage. Deployment in clinical settings requires compliance with U.S. federal and state regulations, clinical validation, and partnership agreements.

Identity Verification

BioSignBox — Solving the Trust Problem in Virtual Care

One of the most critical challenges arising from the expansion of virtual care is the vulnerability of patient identity verification. BioSignBox is our dual-biometric signature technology currently under development to address this challenge proactively.

Dual Biometric Capture

Our proprietary dual-biometric framework engineered to cross-verify intent by combining facial topography parameters, behavioral ink dynamics, and secure session logs—directly confronting the identity verification and beneficiary fraud challenges inherent in virtual care.

Non-Repudiation

The goal is to create a structure that can technically verify — in the event of a future dispute — that consent was given by the actual patient.

Risk Management

Given the U.S. medical litigation environment and regulatory audit risks, this capability aims to serve as a meaningful risk management tool for medical institutions.

Development Status: BioSignBox is currently under active development and has not yet been commercialized. This technology has been filed as a Provisional Patent Application with the USPTO (United States Patent and Trademark Office). The scope of patent protection will be determined upon conversion to a non-provisional application and completion of the USPTO examination process.

Roadmap

The Road to 2027

2026

Technology Foundation & Priority Date Establishment

Implement the core technology architecture — including the P·Q·R clinical engine and BioSignBox — and file 18 Provisional Patent Applications with the USPTO to establish priority dates across the full technology ecosystem.

2026–27

Non-Provisional Conversion & Field Validation

Convert each provisional filing to a non-provisional application within 12 months and advance USPTO examination. Concurrently, conduct technology compatibility reviews and preliminary partnership discussions with U.S. medical groups (MSOs and IPAs).

2027

Global Digital Healthcare Ecosystem

Expand a fully integrated digital healthcare ecosystem connecting mobile, cloud, and AI. The focus is on meaningfully improving access to care for elderly Medicare patients living with chronic conditions.

Intellectual Property

Intellectual Property Status

CyberMDCare has filed a total of 18 Provisional Patent Applications with the USPTO to protect its core technologies.

Provisional Filed

Clinical Data Processing — P (Pain coordinates) · Q (Variable questionnaire) · R (Vital signs) integrated algorithm

Provisional Filed

Clinical Evidence Engine — clinicalEvidenceEngine.ts real-time digital signal processing

Provisional Filed

Biometric Signature System — BioSignBox dual biometric signature + behavioral log binding

Provisional Filed

Cloud Integration Architecture — Bluetooth medical device & mobile real-time data collection and storage

Provisional Patent Notice — All items listed above are currently at the USPTO Provisional Patent Application stage; no patent rights have been granted. Each provisional application must be converted to a non-provisional application within 12 months of filing, and the final scope of patent protection will be determined by the USPTO examination process.

Company

Company Information

Company CyberMDCare
CEO David Kang
Headquarters 18000 Studebaker Rd, Cerritos, CA 90703, USA
Core Platform CMD NOVA SYSTEM (Digital Telehealth Platform)
USPTO Provisional Filings 18 applications filed (pre-examination stage)
Target Market U.S. Medicare Advantage healthcare services market

Connecting People to Longer, Healthier Lives Through Technology

Helping every person live longer and healthier — by elevating both the speed and precision of medicine. CyberMDCare is forging that path through a clinical evidence-based digital healthcare technology system.

Longer and Healthier Lives

Legal

Investor Notices & Forward-Looking Statement Disclaimer

This page contains forward-looking statements regarding CyberMDCare's technology development, business plans, market outlook, and patent filing strategy. Such statements are based on current assumptions, plans, expectations, and estimates.

1. Forward-Looking Statements
A. Statements regarding future business performance, partnership formation, conversion of provisional applications to non-provisional filings, patent registration prospects, market entry, and revenue generation are forward-looking and not statements of established fact.
2. Basis and Assumptions
A. Forward-looking statements are based on CMS published data, the Company's current stage of technology development, analysis of the U.S. healthcare regulatory environment, and internal business plans. The market size figure (approximately $500 billion) is derived from the CMS FY2025 Medicare Advantage expenditure report and does not guarantee the Company's actual revenues.
3. Risk of Differing Outcomes
A. Actual results may differ materially from forward-looking statements due to factors including USPTO patent examination outcomes, changes in U.S. federal and state regulations, healthcare market conditions, technological uncertainties, partnership negotiations, and availability of financing.
4. Special Notice Regarding Provisional Patent Applications
A. The 18 USPTO Provisional Patent Applications referenced on this page are currently in the pre-examination stage; no patent rights have been granted. Each provisional must be converted to a non-provisional application within 12 months of its filing date, and a provisional application itself confers no exclusive patent rights.
5. Corporate Disclosure
A. CyberMDCare is an independent U.S. corporation incorporated in the State of California. The content of this page pertains to the activities of that U.S. entity and is not intended to solicit securities transactions or to induce investment decisions.

This disclaimer has been prepared with reference to the Safe Harbor provisions of Article 125, Paragraph 2 of the Republic of Korea Financial Investment Services and Capital Markets Act.